HDGFL2 and frontotemporal dementia: Elevated levels of HDGFL2 cryptic peptide can be detected in fluid samples from ALS/FTD patients, including those that carry disease-causative mutations but remain asymptomatic (Calliari et al, 2024; Irwin et al, 2024; Seddighi et al, 2024), showing great potential as a biomarker for ALS and FTD.